Crossmark

A randomized double-blind, placebo-controlled, cross-over trial (Vestparoxy) of the treatment of vestibular paroxysmia with oxcarbazepine

Crossref DOI link: https://doi.org/10.1007/s00415-017-8682-x

Published Online: 2017-11-27

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bayer, Otmar

Brémová, Tatiana

Strupp, Michael

Hüfner, Katharina
Funding

Funding for this research was provided by:

Novartis Pharma (DE) (CTRI476BDE12)

Bundesministerium für Bildung und Forschung (EO 0901)
License Information

License valid from 2017-11-27